MedTrace Logo

A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects

NCT04029090 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2026-05-22

Study results available
· View outcomes & findings →

Summary

To evaluate the effect of MCI-186 on the QT interval corrected for heart rate using Fridericia's formula (QTcF)

Conditions

  • Healthy Adult Subjects

Interventions

DRUG

MCI-186

A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.

DRUG

MCI-186

A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.

DRUG

Placebo

A single dose of 0.9% w/v saline over 60 min will be intravenously administered.

Sponsors & Collaborators

  • Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • General Manager · Tanabe Pharma Corporation

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-18
Primary Completion
2018-10-20
Completion
2018-10-23
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04029090 on ClinicalTrials.gov